Min Dai, MD, PhD, joined Duke Pathology's Cytopathology Division as an Assistant Professor on July 6, 2026.
Originally from China, Dai developed an early interest in medicine while growing up in a family of physicians. That early exposure grew into a deep appreciation for both the scientific and human dimensions of patient care and ultimately inspired a career spanning pathology, cancer research, and academic medicine.
Clinically, Dai specializes in cytopathology and genitourinary pathology, with extensive experience in the diagnosis of prostate and bladder cancers, renal neoplasms, and a wide range of benign and malignant diseases. His expertise includes fine-needle aspiration biopsy, exfoliative cytology, and rapid on-site specimen evaluation. He is committed to multidisciplinary collaboration and values close partnerships with clinical colleagues to provide accurate, timely diagnoses that inform patient care.
Dai's research focuses on tumor biology and cancer immunotherapy, with an emphasis on translating laboratory discoveries into advances in cancer treatment. His scholarly work has resulted in more than 30 peer-reviewed publications and book chapters and has been recognized with several national honors, including an award from the Papanicolaou Society of Cytopathology at the 2025 United States and Canadian Academy of Pathology (USCAP) Annual Meeting.
“Teaching and mentorship are central to my academic mission,” said Dai. “I enjoy working with medical students, residents, fellows, and research trainees, helping to cultivate curiosity, critical thinking, and professional growth in the next generation of physicians and scientists.”
Before joining Duke, Dai earned his medical degree and completed graduate training in cancer biology. He subsequently conducted cancer immunotherapy research at the University of Washington before completing pathology residency training at Louisiana State University Health Sciences Center. He then pursued fellowship training in cytopathology and genitourinary pathology at The University of Texas MD Anderson Cancer Center.
Reflecting on his arrival at Duke, Dai expressed enthusiasm about joining the institution.
“I am grateful to join Duke University, an institution I have long admired for its excellence in patient care, research, and education,” said Dai. “Joining Duke represents an exciting new chapter in my professional journey, and I look forward to collaborating with outstanding colleagues across the department while contributing to its missions of clinical excellence, scientific discovery, and education.”
Outside of work, Dai enjoys spending time with his family, watching soccer, and playing soccer with his 10-year-old son. He and his family are excited to become part of the Duke community.